A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Cabozantinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 1 Jun 2018.
- 05 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.